IL-6 controls resistance to radiation by suppressing oxidative stress via the Nrf2-antioxidant pathway in oral squamous cell carcinoma

Br J Cancer. 2016 Nov 8;115(10):1234-1244. doi: 10.1038/bjc.2016.327. Epub 2016 Oct 13.

Abstract

Background: In promoting tumour malignancy IL-6 signalling is considered to have an important role. However, the biological roles of IL-6 on radiosensitivity in oral squamous cell carcinoma (OSCC) remain largely unclear. The objective of this study is to determine the effects and molecular mechanisms of IL-6 on radiosensitivity in OSCC.

Methods: Two OSCC cell lines, and OSCC tissue samples with radioresistant cells were used. We examined the effects of IL-6, or tocilizumab, a humanised anti-human IL-6 receptor antibody, or both on radiosensitivity and DNA damage after X-ray irradiation in vitro. In addition, we investigated the involvement of the Nrf2-antioxidant pathway in IL-6-mediated radioresistant mechanisms using OSCC cell lines and tissues.

Results: Increased levels of IL-6 suppressed radiation-induced cell death, and the blockade of IL-6 signalling by tocilizumab sensitised tumour cells to radiation. The radioresistant effect of IL-6 was associated with decreased DNA damage after radiation. We also found that IL-6 promotes the activation of not only the downstream molecule STAT3 but also the Nrf2-antioxidant pathway, leading to a significant decrease in oxidative stress by upregulating Mn-SOD.

Conclusions: These results indicate that the blockade of IL-6 signalling combined with conventional radiotherapy could augment the treatment response and survival rate in patients with radioresistant OSCC.

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antioxidants / metabolism*
  • Apoptosis / drug effects
  • Carcinoma, Squamous Cell / drug therapy
  • Carcinoma, Squamous Cell / metabolism*
  • Carcinoma, Squamous Cell / radiotherapy
  • Cell Line, Tumor
  • DNA Damage / drug effects
  • Humans
  • Interleukin-6 / metabolism*
  • Mouth Neoplasms / drug therapy
  • Mouth Neoplasms / metabolism*
  • Mouth Neoplasms / radiotherapy
  • NF-E2-Related Factor 2 / metabolism*
  • Oxidative Stress / physiology*
  • Radiation Tolerance / physiology*
  • Radiotherapy / methods
  • Receptors, Interleukin-6 / metabolism
  • STAT3 Transcription Factor / metabolism
  • Signal Transduction / drug effects
  • X-Rays

Substances

  • Antibodies, Monoclonal, Humanized
  • Antioxidants
  • IL6 protein, human
  • Interleukin-6
  • NF-E2-Related Factor 2
  • NFE2L2 protein, human
  • Receptors, Interleukin-6
  • STAT3 Transcription Factor
  • tocilizumab